Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
IMTX | US
0.34
3.23%
Healthcare
Biotechnology
30/06/2024
04/10/2024
10.86
10.48
10.92
10.46
Immatics N.V. a clinical-stage biopharmaceutical company focuses on the discovery and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors which is in Phase 1b clinical trial; IMA203CD8 a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma which is in preclinical stage; and IMA30x an allogenic cellular therapy product candidate which is in preclinical stage. The company also develops TCR Bispecifics products including IMA401 which is in Phase 1b clinical trial; and IMA402 and IMA403 which are in preclinical stages. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen Germany.
View LessLow Market Beta (-0.4 to 0.8)
Value Stock (Price to Book < 3)
Price Below SMA10D
High Short-term Volatility
Smallcap (300M - 2B USD)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
39.5%1 month
45.1%3 months
36.8%6 months
48.9%-
-
2.80
-
-
7.19
8.08
-
-95.19M
1.12B
1.12B
-
-141.64
-
-16.10
-24.32
30.29
13.25
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
1.73
Range1M
2.63
Range3M
2.63
Rel. volume
0.66
Price X volume
2.87M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Innoviva Inc | INVA | Biotechnology | 19.67 | 1.23B | 0.56% | 10.92 | 67.72% |
ANI Pharmaceuticals Inc | ANIP | Biotechnology | 57.83 | 1.22B | 0.57% | 49.40 | 68.04% |
Fluent Inc | COGT | Biotechnology | 11.11 | 1.22B | 3.64% | n/a | 4.87% |
PHATHOM PHARMACEUTICALS INC. | PHAT | Biotechnology | 17.25 | 1.20B | 2.92% | n/a | -216.56% |
ARCUTIS BIOTHERAPEUTICS INC. | ARQT | Biotechnology | 10.02 | 1.17B | -2.05% | n/a | 111.34% |
Travere Therapeutics Inc. | TVTX | Biotechnology | 15.23 | 1.16B | 9.81% | n/a | 2662.08% |
Tyra Biosciences Inc. Common Stock | TYRA | Biotechnology | 22.04 | 1.16B | -1.52% | n/a | 1.70% |
Praxis Precision Medicines Inc | PRAX | Biotechnology | 64.94 | 1.15B | 6.22% | n/a | 0.46% |
Relay Therapeutics Inc. | RLAY | Biotechnology | 6.53 | 1.06B | 0.62% | n/a | 7.50% |
Autolus Therapeutics Plc | AUTL | Biotechnology | 3.98 | 1.06B | 0.25% | n/a | 54.69% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
ARLO TECHNOLOGIES INC | ARLO | Building Products & Equipment | 11.47 | 1.15B | 0.09% | n/a | 19.46% |
Camping World Holdings Inc | CWH | Recreational Vehicles | 23.44 | 1.06B | -0.38% | n/a | 3644.76% |
Malibu Boats Inc | MBUU | Recreational Vehicles | 39.7 | 793.63M | -0.68% | n/a | 1.50% |
Latham Group Inc. | SWIM | Building Products & Equipment | 6.64 | 767.43M | 0.00% | 61.27 | 77.00% |
Ennis Inc | EBF | Building Products & Equipment | 24.31 | 631.67M | 2.36% | 15.15 | 2.42% |
ACCO Brands Corporation | ACCO | Building Products & Equipment | 5.25 | 502.94M | -0.19% | n/a | 174.23% |
Lincoln Educational Services Corporation | LINC | Building Products & Equipment | 11.63 | 366.05M | 0.00% | 47.92 | 88.92% |
ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 21.28 | 334.47M | -4.23% | n/a | 286.96% |
Marine Products Corporation | MPX | Recreational Vehicles | 9.47 | 328.78M | 0.21% | 13.24 | 0.00% |
MCBC Holdings Inc | MCFT | Recreational Vehicles | 17.64 | 292.95M | -0.56% | 35.53 | 26.82% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | 7.19 | 0.76 | Expensive |
Ent. to Revenue | 8.08 | 3,674.48 | Cheaper |
PE Ratio | - | 38.01 | - |
Price to Book | 2.80 | 14.10 | Cheaper |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 36.80 | 74.67 | Lower Risk |
Debt to Equity | - | -1.82 | - |
Debt to Assets | - | 0.26 | - |
Market Cap | 1.12B | 3.73B | Emerging |